Cargando…

Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B

AIM: To evaluate the diagnostic performance of angiotensin-converting enzyme (ACE) on significant liver fibrosis in patients with chronic hepatitis B (CHB). METHODS: In total, 100 patients with CHB who underwent liver biopsy in our hospital were enrolled, and 70 patients except for 30 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi, Ryuichi, Kaji, Kosuke, Namisaki, Tadashi, Moriya, Kei, Kitade, Mitsuteru, Takeda, Kosuke, Kawaratani, Hideto, Okura, Yasushi, Aihara, Yosuke, Furukawa, Masanori, Mitoro, Akira, Yoshiji, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643291/ https://www.ncbi.nlm.nih.gov/pubmed/29085215 http://dx.doi.org/10.3748/wjg.v23.i36.6705

Ejemplares similares

Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development
por: Takeda, Kosuke, et al.
Publicado: (2017)

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model
por: DOUHARA, AKITOSHI, et al.
Publicado: (2015)

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats
por: Nishimura, Norihisa, et al.
Publicado: (2018)

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
por: Asada, Kiyoshi, et al.
Publicado: (2016)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report
por: Kubo, Takahiro, et al.
Publicado: (2020)

The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure
por: Namisaki, Tadashi, et al.
Publicado: (2010)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
por: Asada, Shohei, et al.
Publicado: (2017)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
por: Takagi, Hirotetsu, et al.
Publicado: (2021)

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
por: Seki, Kenichiro, et al.
Publicado: (2018)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases
por: Takaya, Hiroaki, et al.
Publicado: (2017)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Treatment of long-segment Barrett’s adenocarcinoma by complete circular endoscopic submucosal dissection: a case report
por: Kaneko, Miki, et al.
Publicado: (2018)

Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study
por: Kitagawa, Koh, et al.
Publicado: (2022)

Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
por: Tsuji, Yuki, et al.
Publicado: (2020)

Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis
por: Sato, Shinya, et al.
Publicado: (2020)

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa(®) and VIVA(®) Systems
por: Takaya, Hiroaki, et al.
Publicado: (2022)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
por: Akahane, Takemi, et al.
Publicado: (2021)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
por: Akahane, Takemi, et al.
Publicado: (2020)

Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
por: Furukawa, Masanori, et al.
Publicado: (2021)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance
por: YOSHIJI, HITOSHI, et al.
Publicado: (2013)

Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report
por: Mashitani, Tsuyoshi, et al.
Publicado: (2009)

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lp4h1kqt23h24l0akrd7udm83